Capsaicin - Centrexion Therapeutics

Drug Profile

Capsaicin - Centrexion Therapeutics

Alternative Names: Adlea; ALGRX-4975; CNTX-4975; CNTX-4975-05; trans-capsaicin; VLNX-4975

Latest Information Update: 12 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins University
  • Developer Anesiva; Centrexion Therapeutics
  • Class Antipruritics; Catechols; Local anaesthetics; Monounsaturated fatty acids; Non-opioid analgesics; Polyunsaturated alkamides; Small molecules
  • Mechanism of Action Substance P inhibitors; TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuropathic pain
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pain
  • Phase II Neuropathic pain
  • Discontinued Postoperative pain

Most Recent Events

  • 01 Sep 2018 Centrexion Therapeutics initiates a phase III trial in Pain (In adults, In the elderly) in USA (NCT03661996)
  • 01 Sep 2018 Centrexion Therapeutics initiates a phase III trial in Pain (moderate to severe pain associated with knee osteoarthritis, In adults, In the elderly, Treatment-experienced) in USA (Intra-articular) (NCT03660943)
  • 01 Jul 2018 Centrexion Therapeutics initiates enrolment in a phase I trial for Osteoarthritis in USA (NCT03576508)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top